Osiris Completes Enrollment in Stem Cell Trial for Type 1 Diabetes
- Category: DNA RNA and Cells
- Published on Monday, 25 January 2010 02:00
- Hits: 1929
Company Achieves Fourth Milestone Payment from the Juvenile Diabetes Research Foundation
COLUMBIA, MA, USA | January 25, 2010 | Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF’s partnership with Osiris for the development of a therapy for type 1 diabetes.
In total, 63 patients were treated at 20 leading centers in this double-blind, placebo controlled trial. The study is evaluating the safety and efficacy of Prochymal in preserving insulin production in patients newly diagnosed with type 1 diabetes. The trial initially included patients 18 to 30 years of age. In July 2009, after reviewing safety data, the U.S. Food and Drug Administration (FDA) allowed Osiris to expand the trial to include pediatric patients.
“Completing the enrollment phase of this landmark trial represents a significant milestone for the development of stem cell therapies for type 1 diabetes,” said C. Randal Mills, Ph.D., President and CEO of Osiris Therapeutics. “Osiris is deeply committed to developing safe and effective therapies for underserved patient populations, particularly in disease states that afflict children.”
JDRF funds Osiris through its Industry Discovery and Development Partnership program, in which JDRF provides funding to companies to advance promising treatments and cures for type 1 diabetes and its complications through the drug development pipeline. In type 1 diabetes, the patient’s own immune system attacks and destroys insulin-producing islet cells in the pancreas, resulting in the loss of blood-sugar control. Currently, there are no approved treatments for altering the rate of destruction of these critical islet cells, called beta cells. Preclinical studies first conducted by researchers at Genzyme found that MSCs may delay the progression of type 1 diabetes by preserving beta cell function.
Prochymal is a preparation of mesenchymal stem cells (MSCs) formulated for intravenous infusion. The MSCs utilized in Prochymal are isolated from the bone marrow of healthy young adult donors, avoiding the controversy surrounding embryonic and fetal cell sources. They are grown in culture, permitting large-scale production. Because the cells can be expanded, thousands of doses can be produced from a single donation. Studies suggest MSCs are able to safely facilitate tissue repair through a number of mechanisms. Specifically, these studies indicate that MSCs are able to down-regulate severe inflammation and work at the cellular level to rebuild damaged tissue through the coordinated release of tissue specific growth factors.
Prochymal is being evaluated in Phase III programs for steroid-refractory graft versus host disease (GvHD), acute GvHD and Crohn’s disease. Prochymal has been granted Fast Track status by the FDA for GvHD and Crohn’s disease, and is the first stem cell product to receive FDA expanded access approval, making the product available now to patients with life-threatening GvHD. Prochymal also obtained Orphan Drug status for GvHD from the FDA and the European Medicines Agency. Prochymal is also being studied in Phase II trials for the treatment of acute myocardial infarction, pulmonary disease and type 1 diabetes.
About Juvenile Diabetes Research Foundation
JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder and advocate of type 1 research. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is a disease which strikes children and adults suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.
7015 Albert Einstein Drive • Columbia, Maryland 21046 • Ph 443.545.1800 • Fax 443.545.1701 • www.Osir is.com
Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.3 billion to diabetes research, including more than $100 million in FY2009.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is the leading stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, orthopedic and cardiovascular areas. The Company's pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company, with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 49 U.S. patents each having one or more foreign counterparts. Osiris, Prochymal and Chondrogen are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com. (OSIR-G)
In November 2008, Osiris and Genzyme announced a strategic alliance for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, Osiris retains commercialization rights to Prochymal and Chondrogen in the United States and Canada, with Genzyme holding these rights in all other countries.
SOURCE: Osiris Therapeutics, Inc.